target audience: TECH BUYER  Publication date: Oct 2023 - Document type: IDC FutureScape - Doc  Document number: # US51290923

IDC FutureScape: Worldwide Life Sciences 2024 Predictions

By: 

  • Nimita Limaye Loading
  • Lynne Dunbrack Loading
  • Nino Giguashvili Loading
  • Federico Mayr Loading
  • Silvia Piai Loading
  • Michael Townsend Loading
  • Manoj Vallikkat Loading

Content



Related Links

Table of Contents


  • IDC FutureScape Figure

    • Figure: IDC FutureScape: Worldwide Life Sciences 2024 Top 10 Predictions

  • Executive Summary

  • IDC FutureScape Predictions

    • Summary of External Drivers

    • Predictions: Impact on Technology Buyers

    • Prediction 1: By 2024, 70% of Life Sciences Organizations Will Prioritize Security-by-Design, Privacy-by-Design, and Zero Trust Initiatives to Enhance Cyber-Resilience and Build Trust, Fueled by Evolving Regulations

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 2: By 2025, Transformative Patient Experiences Will Be Led by 30% of Life Sciences Firms That Used GenAI to Optimize Trial Design, Hyper-Personalize Content, and Orchestrate Empathetic Interactions

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 3: By 2026, 65% of Life Sciences Companies Will Modernize Digital Infrastructure, Adopting Unified Control Planes to Optimize and Scale Intelligence-Driven Innovation and to Ensure Regulatory Compliance

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 4: Pushed by Data-Driven Market Models and Patient Care Needs, 40% of Life Sciences Companies Will Adopt Integrated Solutions Combining Connected Medical Devices and Digital Health Platforms by 2026

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 5: Fueled by Connected Health Devices and AI-Based Analysis Tools, the Market for Digital Biomarkers Will Double by the End of 2026, Lowering Healthcare Costs While Aiding in R&D and Outcome Measurements

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 6: By 2026, the Adoption of GenAI-Based Drug Design, the Intelligent Supply Chain for Cell and Gene Therapies, and Digital Therapeutics Will Scale the Growth of Precision Therapies by 60%

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 7: Despite the Decreasing Field Sales Head Count, GenAI Enhancements in Commercial Life Sciences Software Will Lead the Industry to a 40% Rise in Personalized Engagements with Healthcare Providers by 2027

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 8: Evolving Home Care Initiatives and Patient Expectations Will Triple the Use of Intelligent Device–Based Drug Delivery Systems by 2027, Followed by Vectorized Antibodies and Gene Delivery Nanocarriers

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 9: By 2027, One-Fourth of the Life Sciences Industry Will Supplement But Not Replace Animal Testing with Computer Simulations, Organoids, and Organ on a Chip, Prioritizing Neurological Diseases

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

    • Prediction 10: Approvals for Clinical Trials Focused on a Brain-Computer Interface Will Double by 2028, Prioritizing Neurorehabilitation While Implementing Strict Guardrails to Ensure Data Privacy and Patient Safety

    • Associated Drivers

    • IT Impact

    • Patient Impact

    • Guidance

  • Advice for Technology Buyers

  • External Drivers: Detail

    • AI Everywhere — Generative AI Takes the Spotlight

    • The Drive to Automate — Maximizing Efficiency and New Opportunities

    • Cybersecurity and Risk — Building Resilience Against Multiplying Threats

    • The Digital Business Imperative — Competitiveness and Outcomes

    • Dynamic Work and Skills Requirements — New Work Mode Era

    • Shifting Tech Regulatory Landscape — Navigating Risk and Opportunity

  • Learn More

    • Related Research